Viridian Therapeutics, Inc. filings document a clinical-stage biotechnology company with common stock listed on Nasdaq under VRDN. The company’s Form 8-K disclosures report financial results, Regulation FD clinical updates, corporate presentations, and material agreements, including underwriting arrangements for common stock offerings.
Viridian’s regulatory filings also cover its thyroid eye disease programs, including elegrobart trial disclosures and updates related to veligrotug, as well as cash resources, research and development activity, and financing transactions. Proxy materials document annual meeting matters, director elections, executive compensation, equity plans, and related governance procedures.
Viridian Therapeutics details its shift toward commercialization in serious and rare autoimmune diseases, led by thyroid eye disease (TED) programs. Lead IV antibody veligrotug has completed two global phase 3 trials in active and chronic TED, with a BLA under FDA Priority Review and a PDUFA target date of June 30, 2026. Subcutaneous follow‑on antibody elegrobart is in two phase 3 REVEAL studies, with topline data expected in the first and second quarters of 2026 and an auto‑injector in development for at‑home use. Viridian is also advancing FcRn inhibitors VRDN‑006 and VRDN‑008, plus an early anti‑TSHR antibody for Graves’ disease and TED. Non‑dilutive funding includes a $70 million Japan collaboration with Kissei and a revenue participation deal with DRI Healthcare for up to $300 million tied to U.S. sales milestones.
Viridian Therapeutics reported a larger net loss in 2025 while advancing its thyroid eye disease (TED) pipeline toward potential commercialization. For 2025, total revenue was $70.8 million and net loss was $342.6 million, compared with revenue of $0.3 million and net loss of $269.9 million in 2024.
Cash, cash equivalents, and marketable securities were $874.7 million as of December 31, 2025, supporting management’s view that, together with potential milestones and anticipated commercial revenue if veligrotug and elegrobart are approved, current plans can be funded through profitability. Veligrotug’s BLA is under Priority Review with a PDUFA target date of June 30, 2026, and a European MAA was submitted in January 2026. Phase 3 elegrobart REVEAL-1 and REVEAL-2 topline data are expected in Q1 and Q2 2026, and VRDN-008 entered phase 1 with data expected in 2H 2026.
Kynam Capital Management and related reporting persons filed an amended Schedule 13G/A disclosing a passive ownership stake in Viridian Therapeutics, Inc. As of 12/31/2025, they collectively reported beneficial ownership of 1,470,541 shares of Viridian common stock, representing 1.54% of the outstanding class.
The filing shows Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang each having shared voting and shared dispositive power over these 1,470,541 shares, with no sole voting or dispositive power. The certification states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Viridian.
Viridian Therapeutics, Inc. shareholder Deep Track Capital and related parties report beneficial ownership of 2,524,833 shares of common stock, representing 2.65% of the class as of December 31, 2025. The shares are held with shared voting and shared dispositive power, and no sole voting or dispositive power.
The ownership percentage is calculated using 95,442,008 shares of Viridian common stock outstanding as of October 31, 2025, as reported in the company’s Form 10-Q. The filers certify that the securities are not held for the purpose of changing or influencing control of Viridian, consistent with a passive Schedule 13G/A Amendment No. 3 filing.
Viridian Therapeutics, Inc. insider Jennifer Tousignant, the company’s Chief Legal Officer, reported a transaction in the company’s common stock. On 12/31/2025, she disposed of 2,272 shares of Viridian common stock at a price of $31.16 per share, coded as a sale. Following this transaction, the filing lists her as beneficially owning 0 shares directly. The footnote explains that the reported shares consist of stock purchased under Viridian’s employee stock purchase plan.
Viridian Therapeutics reported a sharper top line in its Q3 2025 10-Q driven by license activity. Total revenue reached $70.6 million, including $70.0 million of license revenue. The company posted a net loss of $34.6 million, improving from a loss of $76.7 million a year ago, as higher revenue offset increased operating costs. Research and development expense was $86.3 million, and general and administrative expense was $24.3 million in the quarter.
Liquidity remains strong. Cash, cash equivalents and short-term investments totaled $490.9 million as of September 30, 2025, which management states should fund planned operations for at least twelve months. Year to date, net cash used in operating activities was $252.6 million, partly offset by $301.9 million net cash provided by investing activities and $20.8 million from financing. Long-term debt stood at $20.9 million, and in October 2025 the company extended its loan maturity to October 2030. Common shares outstanding were 95,442,008 as of October 31, 2025.
Viridian Therapeutics (VRDN) announced quarterly results by issuing a press release for the quarter ended September 30, 2025. The company furnished the release as Exhibit 99.1 under Item 2.02 of a Form 8-K.
The press release is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act and is not incorporated by reference into other filings. The report was signed by President and Chief Executive Officer Stephen Mahoney.
Viridian Therapeutics (VRDN) reported an insider purchase on a Form 4. On 10/23/2025, Fairmount Healthcare Fund II LP acquired 454,545 shares of common stock at $22 per share (transaction code P). Following the trade, the fund beneficially owned 3,914,458 shares, held indirectly.
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over the securities held by Fairmount Healthcare Fund II LP, and they disclaim beneficial ownership except to the extent of their pecuniary interest. The reporting persons are indicated as a Director and 10% Owner, and the form was filed by more than one reporting person.
Viridian Therapeutics (VRDN) announced an underwritten public offering of common stock. The company agreed to sell 11,425,000 shares at $22.00 per share, for aggregate gross proceeds of approximately $251.35 million before underwriting discounts, commissions, and expenses. Underwriters have a 30‑day option to purchase up to an additional 1,713,750 shares on the same terms. The offering was made under an automatically effective shelf registration statement and is expected to close on October 23, 2025.
Viridian states that the net proceeds, together with existing cash and other expected sources— including a $70 million upfront payment receivable from Kissei in the fourth quarter of 2025, the $55 million upfront payment from a purchase and sale agreement with DRI plus $115 million in potential near‑term milestones under that agreement, and $30 million from a term loan facility—should provide sufficient capital to fund currently anticipated operations. The company also references anticipated revenue from veligrotug and VRDN‑003 sales if each is approved on its anticipated timelines.